$0.63
1.08% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US64132R1077
Symbol
MTVA

NeuroBo Pharmaceuticals Inc Stock price

$0.63
-0.08 11.04% 1M
-1.10 63.50% 6M
-1.40 68.89% YTD
-3.06 82.89% 1Y
-95.15 99.34% 3Y
-1,523.37 99.96% 5Y
-55,199.37 100.00% 10Y
-55,199.37 100.00% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.01 1.08%
ISIN
US64132R1077
Symbol
MTVA
Industry

Key metrics

Basic
Market capitalization
$15.5m
Enterprise Value
$4.3m
Net debt
positive
Cash
$11.2m
Shares outstanding
8.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.5
Financial Health
Equity Ratio
48.8%
Return on Equity
-347.9%
ROCE
-584.0%
ROIC
541.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-25.8m | -
EBIT
$-25.8m | $-24.8m
Net Income
$-24.6m | $-12.7m
Free Cash Flow
$-23.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-27.4% | -
EBIT
-27.5% | 14.1%
Net Income
-48.1% | 53.9%
Free Cash Flow
-56.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.4
FCF per Share
$-2.7
Short interest
2.2%
Employees
-
Rev per Employee
-
Show more

Is NeuroBo Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

NeuroBo Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a NeuroBo Pharmaceuticals Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a NeuroBo Pharmaceuticals Inc forecast:

Buy
89%
Hold
11%

Financial data from NeuroBo Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.84 6.84
0% 0%
-
- Research and Development Expense 19 19
41% 41%
-
-26 -26
27% 27%
-
- Depreciation and Amortization 0.02 0.02
100% 100%
-
EBIT (Operating Income) EBIT -26 -26
27% 27%
-
Net Profit -25 -25
48% 48%
-

In millions USD.

Don't miss a Thing! We will send you all news about NeuroBo Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeuroBo Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
6 days ago
Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data Expected in the Fourth Quarter of 2025 Signed AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 Beyond MASH $17.6 Million in Cash at  End of Second Quarter is E xpected to Fund th...
Neutral
PRNewsWire
7 days ago
Extension is Designed to Assess Early Efficacy and Patient Safety and Tolerability with Longer-Term Exposure to DA-1726 and Further Explore Non-Titrated Maximum Tolerated Dose Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass. , Aug. 6, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, to...
Neutral
PRNewsWire
9 days ago
Partnership Leverages Syntekabio's DeepMatcher® Platform to Expand the Therapeutic Potential of MetaVia's Oral GPR119 Agonist CAMBRIDGE, Mass. , Aug. 4, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a research collaboration with Syntekabio, Inc., a leading artificial intelligence (AI)-dr...
More NeuroBo Pharmaceuticals Inc News

Company Profile

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat neurodegenerative disorders. The company was founded on October 30, 2014 and is headquartered in Boston, MA.

Head office United States
CEO Hyung-Heon Kim
Founded 2014
Website metaviatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today